Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy
| Autor: | Michael H. Rivner, Peter D. Donofrio, Gareth Parry, Michael E. Shy, Mark B. Bromberg, Robert R. Rice, Rup Tandan, Richard J. Barohn, Richard A. Lewis, Wendy C. King, Miriam Freimer, Yadollah Harati, W. W. Campbell, Charles A. Thornton, M. J. Giuliani, Haikady N. Nagaraja, Jerry R. Mendell, D. M. Simpson, Carlayne E. Jackson, John T. Kissel |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Male medicine.medical_specialty Vital capacity Time Factors Randomization Adolescent Neural Conduction Placebo Nerve conduction velocity law.invention FEV1/FVC ratio Double-Blind Method Randomized controlled trial law hemic and lymphatic diseases medicine Humans Aged Aged 80 and over business.industry Immunoglobulins Intravenous Polyradiculoneuropathy Middle Aged medicine.disease Surgery Peripheral neuropathy Polyradiculoneuropathy Chronic Inflammatory Demyelinating Anesthesia Female Neurology (clinical) business |
| Zdroj: | Neurology. 56:445-449 |
| ISSN: | 1526-632X 0028-3878 |
| DOI: | 10.1212/wnl.56.4.445 |
| Popis: | Objective: To determine the efficacy of IV immunoglobulin (IVIg) given patients with untreated chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Methods: A randomized, double-blind, multicenter, investigator-initiated study compared IVIg (Aventis Behring LLC, King of Prussia, PA) with placebo (5% albumin). On days 1, 2, and 21, IVIg (1 g/kg) or placebo was given. The primary outcome measure was the change in muscle strength from baseline to day 42, using the average muscle score (AMS). Secondary outcome measures included change from baseline AMS at days 10 and 21, the Hughes’ functional disability scale, forced vital capacity (FVC), and nerve conduction studies (NCS) of four motor nerves (median, ulnar, peroneal, and tibial). Results: The patients (n = 33) were randomized. Of these, 30 (14 women, 16 men, aged 54 ± 20 years, range 13 to 82) received IVIg and 23 were given placebo (12 women, 11 men, aged 50 ± 18 years, range 23 to 73). Baseline AMS values of the groups were similar (IVIg 7.06 ± 1.31 versus placebo 7.28 ± 1.18, p = 0.53). There were two dropouts in placebo group and one in the IVIg group. Mean AMS improved at day 42 comparing IVIg with placebo (0.63 versus −0.1, p = 0.006). Improved strength was seen by day 10. The placebo group lost strength over this same interval. In the IVIg, 11 subjects improved by the functional disability scale; none worsened. This differed ( p = 0.019) from those in the placebo-treated group (two improved, two got worse, remainder unchanged). Forced vital capacity did not improve with IVIg treatment. IVIg improved ulnar motor distal latency ( p = 0.005), tibial distal compound muscle amplitude ( p = 0.003), and peroneal nerve conduction velocity ( p = 0.03). Conclusions: IVIg improves strength in patients with untreated CIDP by day 10 with continued benefit through day 42; more than one third improve by at least a functional grade on a disability scale. This study provides data supporting IVIg as the initial treatment for CIDP. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|